Familial Hypercholesterolemia. The Genetic Cholesterol Disorder Most Men Don't Know They Have.

Familial hypercholesterolemia is present in approximately 1 in 250 people, making it one of the most common serious genetic disorders in humans. Most of those people do not know they have it. Without treatment, a man with FH has a 50 percent probability of a coronary event before age 50. With early diagnosis and sustained treatment, that excess risk can be largely eliminated. The disorder is both common and correctable, which makes the current diagnosis rate, estimated at below 10 percent in the United States, one of the more significant failures of preventive medicine.

The Mechanism

FH is a disorder of LDL clearance, not LDL production. To understand why that distinction matters clinically, it helps to understand how LDL is normally handled by the liver.

Under normal physiology, LDL circulates in the bloodstream and is cleared by LDL receptors on the surface of hepatocytes (liver cells). These receptors bind LDL particles, pull them into the cell, and degrade them. The liver then adjusts receptor expression based on cellular cholesterol needs: when cholesterol is abundant, receptor expression decreases; when cholesterol is low, expression increases. This feedback loop keeps circulating LDL within a normal range.

In FH, this clearance mechanism is broken at the genetic level. The disorder is caused by a loss-of-function mutation in one of three genes: the LDL receptor gene (LDLR), the apolipoprotein B gene (APOB), or a gain-of-function mutation in PCSK9. LDLR mutations account for more than 85 percent of genetically confirmed FH cases, with over 2,500 distinct pathogenic variants identified. APOB mutations impair the LDL particle’s ability to bind to the receptor even when the receptor is functional. PCSK9 gain-of-function mutations cause the receptor to be degraded more rapidly than normal, reducing LDL clearance. 5 / Solid

In heterozygous FH, one gene copy is defective and one is functional. The result is approximately half the normal LDL receptor capacity. LDL clearance is impaired but not absent, producing LDL levels that typically range from 190 to 400 mg/dL without treatment. In homozygous FH, both copies are defective. LDL levels typically exceed 400 mg/dL from birth and cardiovascular disease presents in childhood or adolescence without aggressive intervention.

The critical clinical implication is the lifetime exposure element. A man with heterozygous FH has had LDL levels between 200 and 350 mg/dL since birth. By age 35 he has accumulated approximately 35 years of atherogenic LDL exposure. The Framingham risk score and other conventional risk calculators were designed for people whose lipid levels represent a recent deviation from normal. FH patients do not fit that model. They have been accumulating plaque since childhood, which is why coronary events in untreated FH occur a full two to three decades earlier than in the general population.

The distinction between FH and diet-driven hypercholesterolemia matters for treatment expectations too. Diet and lifestyle changes produce LDL reductions of 10 to 20 percent in most people. In someone with an LDL of 280 mg/dL, a 20 percent reduction produces an LDL of 224 mg/dL, still more than double the target. The clearance mechanism is broken. You cannot eat your way past a broken receptor.

What the Evidence Shows

The epidemiology of FH is better characterized now than at any point in history, and the findings are consistent across populations. The global prevalence of heterozygous FH is approximately 1 in 250 to 1 in 300 people, based on genetic screening studies in the Netherlands, Denmark, the United Kingdom, and the United States. A landmark cascade screening program in the Netherlands published in the European Heart Journal in 2008 identified over 30,000 FH patients from fewer than 2,000 index cases, confirming the inherited pattern and demonstrating that systematic screening could locate most affected relatives within two generations.

The natural history data from the Medical Research Council’s research on untreated FH, published in the 1990s and since confirmed by multiple registries, established the 50 percent coronary event rate by age 50 in untreated men. The Simon Broome Register, a UK-based prospective FH registry, followed over 600 FH patients from 1980 onward and documented a 100-fold increase in coronary mortality in patients aged 20 to 39 compared to the general population.

The treatment evidence is similarly robust. The TREAT-FH registry, published in the Journal of Clinical Lipidology in 2016 and tracking over 2,600 FH patients across 38 US lipid centers, found that patients achieving an LDL below 100 mg/dL had significantly lower rates of cardiovascular events than those who did not reach target. The PCSK9 inhibitor trials (FOURIER with evolocumab and ODYSSEY Outcomes with alirocumab) both demonstrated substantial additional cardiovascular risk reduction in high-risk patients beyond statin therapy, with event reductions of approximately 15 percent in FOURIER and 15 percent in ODYSSEY Outcomes over a median follow-up period of two to three years.

The Dutch Lipid Clinic Network (DLCN) criteria, the most widely used clinical diagnostic tool for FH, assign points based on LDL level, family history, clinical findings, and genetic confirmation. A DLCN score above 8 indicates FH is very likely. A score of 6 to 8 indicates probable FH. A score of 3 to 5 indicates possible FH. The criteria allow clinical diagnosis without requiring genetic confirmation, which is important because genetic testing identifies a causative mutation in only 60 to 80 percent of clinically diagnosed cases. The remaining cases likely carry mutations in genes not yet fully characterized.

Physical examination findings that support FH diagnosis include tendon xanthomas (cholesterol deposits in the Achilles tendon or extensor tendons of the hands) and corneal arcus before age 45. Xanthelasma (cholesterol deposits around the eyelids) suggests hypercholesterolemia but is less specific for FH. These findings are not present in every FH patient, particularly in heterozygotes who have been partially treated, but when present they are highly specific.

The underdiagnosis problem is well documented. A 2015 analysis in Circulation estimated that fewer than 10 percent of FH patients in the United States carry a documented diagnosis. A 2020 study from the American Heart Association found that even among patients with LDL above 190 mg/dL who had been seen by cardiologists, FH was formally documented in fewer than 25 percent of charts. Many patients were receiving statin therapy without a formal FH diagnosis, meaning cascade screening of first-degree relatives had not been triggered, treatment intensity was likely insufficient, and the clinical record did not accurately reflect the diagnosis.

PCSK9 Inhibitors and Why They Matter for FH

The statin era transformed cardiovascular medicine, but it did not solve FH. A maximum-tolerated statin reduces LDL by 40 to 60 percent. For a patient with heterozygous FH whose untreated LDL is 320 mg/dL, a 50 percent statin reduction brings the LDL to 160 mg/dL. Ezetimibe adds another 15 to 20 percent, bringing it to perhaps 130 mg/dL. The guideline target for FH patients with established cardiovascular disease or additional high-risk features is below 70 mg/dL, and below 55 mg/dL in very high-risk cases. That gap — between what statins plus ezetimibe can achieve in severe FH and where the patient needs to be — is exactly the problem PCSK9 inhibitors were developed to close. 5 / Solid

PCSK9 (proprotein convertase subtilisin/kexin type 9) is a protein that binds to LDL receptors on hepatocytes and targets them for degradation. Inhibiting PCSK9 preserves LDL receptor density on the liver surface, allowing more LDL to be cleared from circulation. PCSK9 inhibitors work through a mechanism that is distinct from statins and additive to them: statins reduce LDL production through HMG-CoA reductase inhibition and upregulate LDL receptor expression, while PCSK9 inhibitors prevent those newly upregulated receptors from being destroyed. The two drug classes are biologically complementary, which is why the combination produces substantially greater LDL reduction than either agent alone.

The two approved monoclonal antibody PCSK9 inhibitors — evolocumab and alirocumab — reduce LDL-C by 50 to 65 percent on top of background statin therapy. In clinical trials, patients combining high-intensity statins with evolocumab achieved median LDL levels below 30 mg/dL. For patients with heterozygous FH, this means that reaching an LDL below 70 mg/dL is achievable in the majority of cases. For homozygous FH, where the LDL receptor may be partially or completely non-functional, the response is more variable and depends on residual receptor activity, but even partial receptor function can be amplified by PCSK9 inhibition.

The cardiovascular outcome data for PCSK9 inhibitors is established in large trials. The FOURIER trial enrolled 27,564 patients with established cardiovascular disease on maximum-tolerated statin therapy and randomized them to evolocumab or placebo. Median LDL in the evolocumab group was reduced from 92 mg/dL to 30 mg/dL. The primary composite cardiovascular endpoint was reduced by 15 percent, and the risk of myocardial infarction was reduced by 27 percent. The ODYSSEY Outcomes trial enrolled 18,924 patients post-acute coronary syndrome and randomized them to alirocumab or placebo, demonstrating a 15 percent reduction in major cardiovascular events and, importantly, a reduction in all-cause mortality in the pre-specified subgroup with baseline LDL above 100 mg/dL. Neither trial showed a safety signal for cognitive function, liver toxicity, or other concerns that had been raised early in PCSK9 inhibitor development. 5 / Solid

For homozygous FH, the treatment challenge is more severe. Most patients with HoFH have LDL levels exceeding 400 mg/dL from early childhood and develop aortic stenosis, coronary artery disease, and xanthomas in the first decade of life without intervention. In this population, LDL apheresis — a process that mechanically filters LDL from the blood through a machine analogous to dialysis — has been the standard of care for decades. PCSK9 inhibitors provide meaningful additional LDL reduction in HoFH patients with some residual LDL receptor function, but patients with null-null mutations (both LDL receptor copies completely non-functional) do not respond to PCSK9 inhibition because there are no receptors for the drug to preserve. Lomitapide, a microsomal triglyceride transfer protein inhibitor that reduces hepatic VLDL and therefore downstream LDL production, is approved specifically for HoFH. Inclisiran, a small interfering RNA that reduces hepatic PCSK9 synthesis rather than blocking the circulating protein, offers twice-yearly dosing and achieves LDL reductions comparable to the monoclonal antibodies.

The practical barrier to PCSK9 inhibitor use in FH patients has historically been insurance authorization, not clinical evidence. Prior authorization requirements often demand documented failure of multiple statins and ezetimibe before PCSK9 inhibitors are approved, which can delay effective treatment by months or years in patients who are accumulating cardiovascular risk during that interval. A formal FH diagnosis in the medical record — using DLCN criteria or genetic confirmation — substantially strengthens the prior authorization case and should be documented explicitly before initiating the authorization process.

The LDL-Years Concept and Why Early Diagnosis Saves Decades

Cardiovascular risk in FH is not simply about how high the LDL is at any given point in time. It is about how long the arteries have been exposed to that LDL. The concept of LDL-years — the cumulative burden of LDL exposure over a lifetime — explains why FH patients experience myocardial infarction in their 30s and 40s while their non-FH counterparts with the same LDL level at 50 may not have their first event until their 60s or 70s. 4 / Promising

Consider two men, both with an LDL of 220 mg/dL at age 50. One has FH and has carried that LDL since birth. The other developed diet- and age-related hypercholesterolemia in his mid-40s. The cumulative LDL exposure of the man with FH is roughly 10 times greater. His coronary arteries have had 50 years of atherogenic LDL, not 5. Standard risk calculators that look only at current LDL, age, blood pressure, and smoking status do not capture this difference, which is a primary reason why the 10-year Pooled Cohort Equations and Framingham Risk Score systematically underestimate cardiovascular risk in FH patients. The DLCN criteria and FH-specific risk models are a partial correction, but the core concept is straightforward: for FH, the clock on atherogenesis started at birth.

This framing has direct clinical implications for treatment initiation. Pediatric FH guidelines from the American Academy of Pediatrics and the National Lipid Association recommend statin initiation in children with FH starting at age 8 to 10, after dietary intervention alone has proven insufficient. This recommendation reflects the LDL-years logic: every year of treatment in childhood is a year of plaque accumulation prevented. Long-term follow-up data from the Netherlands, where pediatric FH treatment was adopted earlier than in most other countries, has demonstrated that patients who began statin therapy before age 18 have significantly lower rates of cardiovascular events in adulthood than those who began treatment later, even when adult LDL levels are similar between the two groups. 4 / Promising

The inverse implication is equally important. A 40-year-old with newly diagnosed FH who has had an LDL of 280 mg/dL since birth has already accumulated 40 years of atherogenic exposure before treatment began. Even if LDL is brought to 55 mg/dL after diagnosis, the existing plaque burden reflects those prior decades. This does not mean treatment is futile — statin therapy has been shown to stabilize and partially regress atherosclerotic plaque, and reducing LDL dramatically lowers the risk of plaque rupture regardless of existing burden. But it does mean that a 40-year-old newly diagnosed FH patient requires more aggressive cardiovascular assessment at baseline, including evaluation for subclinical coronary artery disease, than a 40-year-old without FH who developed borderline LDL last year.

Coronary artery calcium (CAC) scoring is particularly useful in this context. CAC directly measures calcified atherosclerotic plaque in the coronary arteries and provides an objective assessment of accumulated cardiovascular damage that is independent of current LDL levels. In FH patients with elevated LDL-years but no clinical events, a high CAC score confirms the need for aggressive treatment targets and may justify PCSK9 inhibitor initiation beyond what standard risk thresholds would indicate. A CAC score of zero in an FH patient, while reassuring, does not override the genetic risk — it simply means that plaque accumulation, while present at a cellular level, has not yet calcified to detectable levels.

The LDL-years framework also explains the particular importance of cascade screening in FH families. When a 45-year-old man is diagnosed with FH, his 20-year-old child who carries the same mutation has already accumulated 20 years of atherogenic LDL exposure. Identifying that child now and beginning treatment immediately saves the next several decades of LDL-years. Waiting until the child develops symptoms, or until an incidental lipid panel in their 40s flags a high LDL, allows two additional decades of plaque accumulation to proceed unchecked. The diagnostic moment for the index patient is therefore the optimal time to initiate cascade screening, not a reminder to pass along at some future family gathering.

What to Do This Week

1. If your LDL has ever been above 190 mg/dL without a clear secondary cause (hypothyroidism, kidney disease, liver disease, medications), ask your physician specifically whether FH has been evaluated using the Dutch Lipid Clinic Network criteria. Do not accept “your cholesterol is high and you are on a statin” as a complete answer. Ask whether FH was considered.

2. If a parent, sibling, or child had a cardiac event before age 55 (men) or 65 (women), and your own LDL is above 160 mg/dL, this combination should prompt formal FH evaluation at your next visit. Bring the family history explicitly. Do not assume your physician has it in the chart.

3. If you are already on statin therapy for high LDL, ask what your ApoB target is. For most FH patients with additional risk factors, the target is below 70 mg/dL for ApoB. If your current treatment regimen is not reaching that target, combination therapy options (ezetimibe, PCSK9 inhibitors, bempedoic acid) should be discussed.

4. If you are diagnosed with FH, communicate this specifically to your first-degree relatives: parents, siblings, and children over age 10. Each of them has a 50 percent probability of carrying the same mutation. The most effective way to find FH in a population is to start from confirmed cases and screen outward. You are that starting point.

5. Ask your cardiologist or lipid specialist whether your coronary artery calcium score has been measured. In FH patients, the CAC score provides additional stratification of cardiovascular risk beyond LDL alone and can guide decisions about treatment intensity, particularly in younger patients where the absolute risk calculators tend to underestimate lifetime risk.

One practical point deserves emphasis regarding treatment monitoring. FH patients on combination therapy require more frequent lipid panels than the standard annual check most primary care practices default to. A patient starting a PCSK9 inhibitor should have ApoB and LDL rechecked at 4 to 6 weeks to confirm treatment response, and annually thereafter once at target. If the treating physician is not a lipid specialist or cardiologist, it is worth asking about the monitoring schedule at the initiation of each new medication. Getting to target matters, but knowing whether you are at target requires measurement on a schedule that tracks the therapy.

The diagnosis of familial hypercholesterolemia changes the clinical equation substantially: the disease began at birth, the treatment targets are more aggressive, and the screening obligation extends to your entire immediate family. What it does not change is the prognosis for patients who receive appropriate treatment early.